Evelo has several product candidates in development with the potential to treat a range of inflammatory diseases.
More than one billion people worldwide suffer from chronic inflammatory diseases. Because of the limitations of treatments that are currently available, many of these people are undertreated or not treated at all. Evelo’s product candidates have the potential to address this unmet need.
We currently have two products in clinical development: EDP1815 and EDP2939 for the treatment of inflammatory diseases.
Our R&D teams are also working to harness the ability of microbial extracellular vesicles (EVs) – tiny particles released by microbes – to influence the immune system via SINTAX. Preclinically, these EVs have been observed to show potential to treat inflammatory diseases.
Product Candidate
Indication
Preclinical Development
Phase 1
Phase 2
Phase 3
Psoriasis
A dose-ranging Phase 2 trial that evaluated EDP1815 for the treatment of mild to moderate psoriasis. The trial evaluated three doses of EDP1815 versus placebo in approximately 225 individuals, over a 16-week treatment period.
Learn more about our work in Inflammatory DiseasesAtopic dermatitis
A 16 week, double-blind, placebo-controlled trial in 300 patients. Randomized into one of three cohorts – each cohort has ~100 patients randomized in a 3:1 ratio (75 to EDP1815 and 25 to placebo).
- Cohort 1: Dose of 1.6 x 1011 total cells of EDP1815 or matching placebo administered as two capsules once daily.
- Cohorts 2 & 3: Dose of 6.4 x 1011 total cells of EDP1815 or matching placebo administered as two capsules once daily or one capsule twice daily, respectively.
- Plan to add an additional cohort of patients to assess the faster release capsules is being finalized. This cohort, if approved by regulatory agencies, will be dosed at 8.0 x 1011 total cells of EDP1815 or placebo as one capsule, once daily.
Inflammation
Initiation of clinical development of EDP2939, Evelo’s first microbial extracellular vesicle (EV) candidate, in 3Q 2022.
Learn more about our work in Inflammatory DiseasesOncology
Preclinical candidate in the next wave of SINTAX-based medicines, microbial extracellular vesicles (EVs).
Neuro-inflammation
Chronic inflammation of the nervous system is believed to be a driver of neuro-inflammatory diseases (i.e. Multiple Sclerosis) and is also associated with neurodegenerative diseases (i.e. Alzheimer’s disease, Parkinson’s disease, Huntington’s disease, etc.) Evelo is studying the impact of single strains of microbes on neuro-inflammation in preclinical studies. The most notable effect is the clearance of inflammatory cells in the spinal cord by these microbes. SINTAX is an effective portal to central inflammatory pathways without the need to cross the blood-brain barrier. This is potentially transformational in the treatment of neuroinflammatory and neurodegenerative diseases which have an inflammatory drive to their pathology.
Product Candidate
EDP1815
Indication
Psoriasis
Phase
Phase 3
A dose-ranging Phase 2 trial evaluating EDP1815 for the treatment of mild to moderate psoriasis. The trial is evaluating three doses of EDP1815 versus placebo in approximately 225 individuals, over a 16-week treatment period.
Learn more about our work in Inflammatory DiseasesProduct Candidate
EDP1815
Indication
Atopic dermatitis
Phase
Phase 2
EDP1815 is entering a Phase 2 trial in atopic dermatitis in 3Q 2021.
Learn more about our work in Inflammatory DiseasesProduct Candidate
EDP2939
Indication
Inflammation
Phase
Preclinical Development
Preclinical candidate is the next wave of SINTAX-based medicines, microbial extracellular vesicle (Es).
Learn more about our work in Inflammatory DiseasesProduct Candidate
EDP1908
Indication
Oncology
Phase
Preclinical Development
Preclinical candidate in the next wave of SINTAX-based medicines, microbial extracellular vesicles (EVs).
Product Candidate
Research
Indication
Neuro-inflammation
Phase
Preclinical Development
Chronic inflammation of the nervous system is believed to be a driver of neuro-inflammatory diseases (i.e. Multiple Sclerosis) and is also associated with neurodegenerative diseases (i.e. Alzheimer’s disease, Parkinson’s disease, Huntington’s disease, etc.) Evelo is studying the impact of single strains of microbes on neuro-inflammation in preclinical studies. The most notable effect is the clearance of inflammatory cells in the spinal cord by these microbes. SINTAX is an effective portal to central inflammatory pathways without the need to cross the blood-brain barrier. This is potentially transformational in the treatment of neuroinflammatory and neurodegenerative diseases which have an inflammatory drive to their pathology.
Product Candidate
Research
Indication
Metabolism
Phase
Preclinical Development
Metabolic syndrome, which affects more than 30% of adults in the US, increases one’s risk of developing cardiovascular disease and type 2 diabetes. Metabolic syndrome is often accompanied by low grade chronic inflammation, which is has been implicated in both its development and progression of associated pathologies. Evelo is investigating the therapeutic potential of single strains of microbes on multiple aspects of metabolic syndrome (i.e., excess body fat, insulin resistance, triglyceride levels) in preclinical models.
Partnership
Connect with us
Let’s work together to spark global change. We seek to partner with pharmaceuticals, biotechs, universities, and other organizations that are committed to transforming the current healthcare paradigm.
